Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: citric acid; croscarmellose sodium; lactose monohydrate; povidone; mannitol; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; citric acid; povidone; croscarmellose sodium; lactose monohydrate; pregelatinised maize starch; mannitol; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; citric acid; lactose monohydrate; mannitol; magnesium stearate; povidone; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; mannitol; pregelatinised maize starch; lactose monohydrate; citric acid; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; crospovidone; hyprolose; lactose monohydrate; purified talc; magnesium stearate; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; hyprolose; magnesium stearate; crospovidone; purified talc; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 10 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; purified talc; crospovidone; lactose monohydrate; magnesium stearate; hyprolose; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: purified talc; crospovidone; lactose monohydrate; magnesium stearate; colloidal anhydrous silica; hyprolose; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; crospovidone; colloidal anhydrous silica; lactose monohydrate; purified talc; hyprolose; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 10 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; crospovidone; lactose monohydrate; hyprolose; purified talc; magnesium stearate; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.